This trial will test a new combination drug to treat triple negative breast cancer.
1 Primary · 5 Secondary · Reporting Duration: 7 years
Active Control
Experimental Treatment
668 Total Participants · 2 Treatment Groups
Primary Treatment: adagloxad simolenin combined with OBI-821 · No Placebo Group · Phase 3
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:California | 100.0% |
65+ | 100.0% |
Long Beach Memorial Medical Center | 100.0% |
Met criteria | 100.0% |
Phone Call | 100.0% |